AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- Breast cancer patients who used menopausal hormone therapy before their diagnosis had a reduced breast cancer mortality, compared with never-users of hormone therapy in the large epidemiologic California Teachers Study.
Users of estrogen-plus-progestin hormone therapy (HT) who developed breast cancer had an unadjusted 63% relative risk reduction in breast cancer-specific mortality, compared with HT never-users with the malignancy.
The fully adjusted reduction in the risk of breast cancer mortality in patients with a history of estrogen-progestin HT was 47%, compared with HT never-users, Sarah F. Marshall of the University of California, Irvine, reported at the San Antonio Breast Cancer Symposium.
In breast cancer patients with a history of estrogen-only HT use, the unadjusted relative risk reduction in mortality due to breast cancer was 36%, compared with HT never-users.
However, upon fully adjusting for race; lymph node status; tumor stage, size, grade, and estrogen receptor status; comorbidities, type of treatment, smoking, body mass index, and physical activity, the relative risk reduction shrank to 18%, which was no longer statistically significant, according to Ms. Marshall.
The California Teachers Study is an ongoing epidemiologic study involving 133, 479 female teachers and administrators.
Ms. Marshall reported on 2,783 postmenopausal participants diagnosed with breast cancer during 1995-2005. Their mean age at diagnosis was 68 years.
Source: HighBeam Research, Study: HT cuts breast cancer mortality 47%.(NEWS)